Every 10-Q that Scholar Rock Holding Corporation (SRRK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SRRK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRRK filings page.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on spinal muscular atrophy (SMA) and other rare neuromuscular diseases. Its lead antibody, apitegromab, has positive Phase 3 SAPPHIRE data in non‑ambulatory Type 2/3 SMA, and a resubmitted Biologics License Application was accepted by the FDA with a September 30, 2026 PDUFA action date. A marketing authorization application for SMA is also under review in Europe.
For the six months ended June 30, 2026, the company reported a net loss of $215.4 million, driven by research and development expense of $110.0 million and general and administrative expense of $100.9 million as it builds commercial infrastructure. Cash, cash equivalents and marketable securities totaled $492,088 (thousands), and management expects this to fund operations into the second half of 2027.
During 2026, Scholar Rock strengthened its balance sheet through a new term loan facility with Blue Owl, drawing $200.0 million, and via an at‑the‑market equity program that raised $160.8 million. Key programs include the ONYX long‑term extension in SMA, Phase 2 OPAL in SMA patients under age two, Phase 2 FORGE in FSHD, and a Phase 1 study of SRK‑439.
Scholar Rock Holding Corporation reported a larger quarterly net loss as it continues investing in late‑stage neuromuscular programs and launch readiness for apitegromab. For the three months ended March 31, 2026, net loss widened to $105.5 million, compared with $74.7 million a year earlier, driven mainly by higher general and administrative spending linked to commercialization preparation and headcount growth.
Research and development expense rose modestly to $51.8 million, with spending concentrated on apitegromab clinical and regulatory activities and the broader anti‑myostatin pipeline. Scholar Rock strengthened its balance sheet, closing the quarter with $479.9 million in cash, cash equivalents, and marketable securities, helped by an at‑the‑market equity program that raised $111.8 million and by drawing $200 million under a new term loan facility with Blue Owl.
Regulatorily, the company resubmitted its Biologics License Application for apitegromab in SMA in March 2026, which the FDA accepted with a September 30, 2026 PDUFA action date. The resubmission followed a 2025 Complete Response Letter tied to a third‑party fill‑finish facility, not to apitegromab’s efficacy or safety data.
Scholar Rock (SRRK) reported Q3 2025 results with a larger loss as it prepares for potential commercialization. Net loss was $102.2 million for the quarter and $287.0 million for the nine months. Operating expenses rose to $103.6 million in Q3, driven by higher R&D to support apitegromab and pipeline work, and sharply higher G&A for launch readiness, equity-based comp, and professional services.
Liquidity remains solid. Cash, cash equivalents and marketable securities totaled $369.6 million as of September 30, 2025, with long‑term debt of $99.6 million. The company raised $91.7 million net through its ATM in 2025 (2,767,000 shares) and drew an additional $50.0 million term loan on September 29, bringing total term loans funded to $100.0 million. Shares outstanding were 102,007,457 as of November 5, 2025.
Regulatory update: The FDA issued a Complete Response Letter in September tied to site‑related observations at a third‑party fill‑finish facility; no efficacy or safety issues were cited. Scholar Rock held a Type A meeting in November and plans to resubmit the apitegromab BLA when the facility is reclassified. The EMA validated the apitegromab MAA in March 2025.